证券代码：300633 证券简称：开立医疗 公告编号：2023-045 深圳开立生物医疗科技股份有限公司监事会 关于公司 2023 年限制性股票激励计划激励对象名单 的核查意见及公示情况说明 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 公司监事会核查了本次拟激励对象的名单、身份证件、拟激励对象与公司或 子公司签订的劳动合同（或聘用合同）、拟激励对象在公司或子公司担任的职务 及其任职情况等。 二、监事会的核查意见 监事会根据《管理办法》、《自律监管指南》等有关法律、法规、规范性文件 的规定，对本次激励计划激励对象名单进行了核查，并发表核查意见如下： 1、本次激励计划激励对象为公司微创外科业务团队员工（包含外籍员工） 及董事会认为应当激励的其他人员，均为公司或子公司正式在职员工。本计划激 励对象不包括独立董事、监事，也不包括单独或合计持有公司 5%以上股份的股 东或实际控制人及其配偶、父母、子女。 一、公示情况及核查方式 深圳开立生物医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 21 日召开第三届董事会第十三次会议、第三届监事会第十三次会议 ...

长城证券股份有限公司 | 项 目 | 工作内容 | | --- | --- | | 1．公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3．募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 1 次 | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4．公司治理督导情况 | | | （1）列席公司股东大会次数 | 次 0 | | （2）列席公司董事会次数 | 0 次 | | （3）列席公司监事会次数 | 0 次 | | 5．现场检查情况 | | | 项 目 | 工作内容 | | --- | --- | | （1）现场检查次数 | 1 次，对募集资金存放与使用情况进行 | | | 了核 ...

证券代码：300633 证券简称：开立医疗 编号：2023-010 深圳开立生物医疗科技股份有限公司 2023 年 8 月 23-25 日投资者关系活动记录表 | --- | --- | --- | --- | |------------|--------------|-------|------------| | | 特定对象调研 | □ | 分析师会议 | | 投资者关 | □ 媒体采访 | □ | 业绩说明会 | | 系活动类别 | □ 新闻发布会 | □ | 路演活动 | | | 现场参观 | □ | 一对一沟通 | | | 电话会议 | □ | 其他 | 国君医药、中邮基金、摩根斯坦利、广发资管、广发基金、中信建 参与单位 名称 投、华泰证券、德邦证券、信达证券、望正资产、信达医药、汇添 富基金、中海基金、大成基金、华安基金、太平基金、开源医药 时间 2023 年 8 月 23-25 日 地点 公司会议室 上市公司 接待人员 董事会秘书李浩、证券事务代表吴坚志 问：上半年公司超声收入增长较好的原因？ 答：上半年公司超声收入增长较好，主要是国际超声业务带动， 具体原因包括两个方面，一是海外疫情管控放开 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,043,339,390.90, representing a 24.87% increase compared to CNY 835,528,794.61 in the same period last year[17]. - The net profit attributable to shareholders for the first half of 2023 was CNY 273,059,845.78, a 56.18% increase from CNY 174,835,885.10 in the previous year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 273,092,726.63, reflecting a 67.97% increase from CNY 162,586,812.07 in the same period last year[17]. - The basic earnings per share for the first half of 2023 was CNY 0.6382, up 56.19% from CNY 0.4086 in the previous year[17]. - The diluted earnings per share for the first half of 2023 was CNY 0.6349, an increase of 55.38% compared to CNY 0.4086 in the same period last year[17]. - The company's revenue for the first half of 2023 showed steady growth, with net profit attributable to shareholders significantly increasing, aligning with the company's initial plans[35]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2023, representing a 25% year-over-year growth[48]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2023, representing a year-over-year growth of 20%[49]. Research and Development - The company's R&D expenses accounted for nearly 20% of its operating revenue during the reporting period[2]. - The company is focused on the development of new products and technologies to enhance its market position[2]. - The company is committed to continuous R&D investment to maintain its competitive edge and respond quickly to market demands[34]. - The company has over 600 R&D personnel, with more than 40% holding master's degrees or higher, and has received multiple national and provincial recognitions for its innovation capabilities[61]. - R&D expenses for 2020, 2021, and 2022 were CNY 237.42 million, CNY 263.06 million, and CNY 328.96 million, representing 20.41%, 18.21%, and 18.66% of total revenue respectively[61]. - The company is investing in R&D for advanced imaging technologies, with a budget allocation of 200 million RMB for 2023, aiming to innovate and expand its product line[48]. Market Position and Strategy - The medical device market is highly competitive, with numerous participants, and the company must maintain its competitive advantages to avoid market elimination[3]. - The company has established a strong competitive advantage in the international medical device market, particularly in ultrasound and endoscope sectors[25]. - The company continues to focus on expanding its product offerings and market presence, particularly in the ultrasound diagnostic equipment sector[17]. - The company aims to contribute to the rise of domestic medical devices by developing high-end medical equipment with independent intellectual property rights[25]. - The company is focusing on expanding its multi-product strategy, transitioning from diagnostic to "diagnostic + treatment" solutions[32]. - The company is actively pursuing new strategies for market expansion, leveraging its innovative product pipeline to capture growth opportunities in the medical device sector[41][42]. Product Development and Innovation - The company has developed a comprehensive range of ultrasound products, including high-end, mid-range, and low-end devices, meeting diverse clinical application needs across various fields[27]. - The high-end ultrasound products S60 and P60 series have received high recognition from experts in top-tier hospitals, particularly excelling in obstetrics and gynecology compared to imported counterparts[27]. - The company has successfully obtained NMPA Class III medical device registration for its intravascular ultrasound diagnostic equipment and disposable intravascular ultrasound diagnostic catheters, becoming the only domestic ultrasound manufacturer with such capabilities[31]. - The new ultra-high-end ultrasound platform received CE (MDR) certification in December 2022, expected to enhance market competitiveness and brand influence upon launch[27]. - The company has expanded its product line in the endoscope sector, including HD350, HD400, HD500, and HD550 series, covering high, mid, and low-end markets[28]. - The introduction of the SFI imaging technology and the combination with the HD-550 system provides a complete solution for early diagnosis and treatment of diseases[28]. - The company has launched the ProPet series for veterinary ultrasound applications, further broadening its ultrasound product market[32]. - The company’s ultrasound products have achieved significant advancements, with a complete range of high, mid, and low-end products developed over 20 years[32]. Financial Position - Total assets at the end of the reporting period were CNY 3,692,742,172.90, a 4.19% increase from CNY 3,544,216,145.59 at the end of the previous year[17]. - The net assets attributable to shareholders at the end of the reporting period were CNY 3,000,049,043.36, reflecting a 9.50% increase from CNY 2,739,802,619.18 at the end of the previous year[17]. - The weighted average return on equity for the first half of 2023 was 9.48%, an increase of 2.37% from 7.11% in the previous year[17]. - The company's gross profit margin has improved due to an increase in the proportion of high-end products sold, while the ratio of operating expenses to revenue has decreased[37]. - The company reported a total investment of ¥27,630,500.99 during the reporting period, a decrease of 32.51% from ¥40,941,025.43 in the same period last year[79]. - The company has ongoing major non-equity investments, including the construction of a medical device industrial base with an investment of ¥1,139,899.51, which is 98.46% complete[81]. Risks and Challenges - The company faces risks related to overseas sales, including currency fluctuations and geopolitical tensions, which could adversely affect its international business[2]. - The company acknowledges the potential impact of healthcare policy changes on market pricing and procurement processes[4]. - The company continues to face various risks, with specific measures outlined in the report[101]. - The company has not experienced any significant litigation or arbitration matters during the reporting period[112]. - The company has not engaged in any major related party transactions during the reporting period[114]. Corporate Governance and Shareholder Information - The company does not plan to distribute cash dividends or issue bonus shares[6]. - The annual general meeting held on May 10, 2023, had an investor participation rate of 57.44%[105]. - The company has not encountered any issues regarding the use and disclosure of raised funds[88]. - The company has not made any capital increases from capital reserves during the reporting period[106]. - The company has no significant changes in the conditions affecting the performance of contracts during the reporting period[118]. - The company has no major risks of contract non-performance during the reporting period[118].

深圳开立生物医疗科技股份有限公司 2023 年半年度募集资金存放与使用情况专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 募集资金基本情况 （一）实际募集资金金额及资金到账情况 经中国证券监督管理委员会证监许可〔2021〕668 号文核准，并经深圳证券 交易所同意，本深圳开立生物医疗科技股份有限公司（以下简称"公司"）由主 承销商长城证券股份有限公司（以下简称"长城证券"）采用定向发行方式，向 特定对象非公开发行股份人民币普通股（A 股）股票 27,851,745 股，发行价为每 股人民币 27.79 元，共计募集资金 773,999,993.55 元，坐扣承销费用 1,886,792.45 元后的募集资金为 772,113,201.10 元，其中 245,167,501.10 元已由长城证券于 2021 年 12 月 21 日汇入公司在中国工商银行股份有限公司南山支行开立的账号 为 4000020319200789913 的人民币账户，526,945,700.00 元已由长城证券于 2021 年 12 月 21 日汇入公司在汇丰银行(中国)有 ...

深圳开立生物医疗科技股份有限公司 2023 年限制性股票激励计划激励对象名单 | | | 获授的限制性 | 占本激励计划授予 | 占目前总 | | --- | --- | --- | --- | --- | | 人员 | 国籍 | 股票数量 | 限制性股票总数的 | 股本的比 | | | | （股） | 比例 | 例 | | YANG MEI | 加拿大 | 1,597,000 | 48.48% | 0.37% | | Helga Schemm | 德国 | 107,100 | 3.25% | 0.02% | | 微创外科业务团队员工及董事 会认为应当激励的其他人员 | 中国 | 1,589,900 | 48.27% | 0.37% | | （共 32 人） | | | | | | 合计 | | 3,294,000 | 100.00% | 0.76% | 一、限制性股票激励计划分配情况表 注：上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致，下同。 二、微创外科业务团队员工及董事会认为应当激励的其他人员名单 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | ...

证券代码：300633 证券简称：开立医疗 公告编号：2023-041 深圳开立生物医疗科技股份有限公司 第三届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2023 年 8 月 21 日，深圳开立生物医疗科技股份限公司（以下简称"公司"） 第三届监事会第十三次会议在深圳市光明区光电北路 368 号开立医疗大厦一楼 会议室召开。本次会议由监事会主席陈欣主持。应出席监事 3 名，实际出席监事 3 名。符合《公司章程》规定的法定人数，本次监事会会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，一致通过了如下决议： 1、审议通过《关于公司 2023 年半年度报告及其摘要的议案》 经审核，监事会认为：董事会编制和审核公司 2023 年半年度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司在中国证监会指定的创业板信息披露网站巨潮资讯网披 露的《2023 年半年度报告》以及《2023 年半 ...

证券代码：300633 证券简称：开立医疗 编号：2023-009 深圳开立生物医疗科技股份有限公司 2023 年 7 月 13-14 日投资者关系活动记录表 | --- | --- | --- | |------------|--------------|--------------| | | 特定对象调研 | □ 分析师会议 | | 投资者关 | □ 媒体采访 | □ 业绩说明会 | | 系活动类别 | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | □ 一对一沟通 | | | 电话会议 | □ 其他 | 兴业证券、建信基金、富荣基金、中融基金、康曼德资本、睿远基 金、先锋基金、中欧瑞博、前海联合基金、基石资本、石智（泉 州）基金、鸿昇金融集团、广东乐赢、上汽颀臻、相聚资本、国信 参与单位 名称 证券投资总部、创金合信基金、景顺基金、惠升基金、平安医药、 兴证医药、东吴医药、华夏基金、民生医药、华商基金、华安基 金、广发基金 时间 2023 年 7 月 13-14 日 地点 公司会议室 上市公司 接待人员 董事会秘书李浩、证券事务代表吴坚志 问：公司 2023 年半年度净利润增速较好的原因？ ...

证券代码：300633 证券简称：开立医疗 编号：2023-008 深圳开立生物医疗科技股份有限公司 2023 年 5 月 15-26 日投资者关系活动记录表 | --- | --- | --- | |------------|--------------|--------------| | | 特定对象调研 | □ 分析师会议 | | 投资者关 | □ 媒体采访 | □ 业绩说明会 | | 系活动类别 | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | □ 一对一沟通 | | | 电话会议 | □ 其他 | 崇山投资、申万宏源、香港盈科、嘉合基金、易方达基金、中庸资 产、世豪资本、华安证券、乐中控股、珠海乐中、长青藤、诚诺资 产、光大证券、兴合基金、兰馨亚洲基金、高盛资管、花旗银行、 参与单位 名称 万利富达、招商资管、东莞证券、财信证券、华创证券、安信资 管、景顺长城基金、汇添富基金、财通基金、国华兴益保险资产、 华福证券、工银瑞信、华金证券、国联证券、开源证券 时间 2023 年 5 月 15-26 日投资者关系活动记录表 地点 公司会议室 上市公司 接待人员 董事长陈志强、董事会秘书李浩、 ...

证券代码：300633 证券简称：开立医疗 编号：2023-007 深圳开立生物医疗科技股份有限公司 2023 年 5 月 10-11 日投资者关系活动记录表 | --- | --- | --- | |------------|--------------|------------| | | 特定对象调研 | 分析师会议 | | 投资者关 | □ 媒体采访 | 业绩说明会 | | 系活动类别 | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | 一对一沟通 | | | □ 电话会议 | 其他 | 华夏基金、彤源投资、世豪资本、连捷投资、怀德资本、方正证券 医药、南方基金、富荣基金、森瑞投资、国信医药、正奇资本、东 参与单位 名称 方合盈、深圳诚诺资产、东方睿信基金、千榕资产、华泰医药、申 万宏源医药、丹麓资本、红筹投资、德摩资本、石智基金、珠海乐 中投资、光大证券医药、上海理成资产、上海沣杨资产、鑫鼎基金 时间 2023 年 5 月 10-11 日投资者关系活动记录表 地点 公司会议室 上市公司 接待人员 董事长陈志强、董事会秘书李浩、财务总监罗曰佐 问：日本内窥镜企业在国内设立工厂，公司如何看待？ ...